


A Quick Look at Using Prevnar13™ (PCV13) Pneumococcal Conjugate Vaccine

<p>Indications for Use of PCV13 (Prevnar13; Wyeth) & Schedule</p> <p><u>Routine Schedule for Children who Never Received PCV7</u></p> <ul style="list-style-type: none"> · 4 doses: a 3-dose primary series at 2, 4, 6 months and a booster dose at 12-15 months <ul style="list-style-type: none"> - Children who do not start or continue the series on time may need less doses to complete the series - Children with an incomplete schedule who are: <ul style="list-style-type: none"> · Healthy & age 24 through 59 mo will need 1 dose · High risk & age 24 through 71 mo will need 2 doses <p><u>Minimum Intervals</u></p> <ul style="list-style-type: none"> · 4 weeks between doses given <u>before</u> age 12 months · 8 weeks between doses given <u>at/after</u> age 12 months 	<p>Vaccine Administration</p> <p>Intramuscular (IM) injection in the anteriolateral thigh or deltoid of the arm</p> <ul style="list-style-type: none"> · 1 inch needle; 22-25 gauge · Professional judgment is appropriate when selecting needle length and site · Can be given with other vaccines¹, at the same visit (use separate sites; space at least 1 inch apart) <hr/> <p>Storage and Handling</p> <ul style="list-style-type: none"> · Store in the refrigerator between 35°-46° F (2°-8°C) · Do NOT freeze · Keep in the original box <div data-bbox="1263 436 1448 613" data-label="Image">  </div>
--	---

Contraindications

- An anaphylactic reaction to a prior dose of Pneumococcal Conjugate Vaccine (PCV7 or PCV13) or any diphtheria-toxoid containing vaccine
- An anaphylactic reaction to a component of PCV13

Precautions

- Moderate to severe acute illness

Transitioning from PCV7 to PCV13*

- Children ages 6 weeks through 59 months who are unvaccinated or started a PCV7 series
 - Complete the series, using PCV13 for all remaining recommended doses (based on age at visit)
- Children ages 14 through 59 months that have completed a PCV7 series
 - Give one dose of PCV13
 - Minimum interval of 8 weeks since the last dose of PCV7
- High Risk Children
 - Ages 24 through 71 months
 - Give 1-2 doses of PCV13*
 - Doses needed depend on number of PCV7 doses given or if an age-appropriate PCV7 series was completed
 - Ages 6 through 18 years
 - May give one dose of PCV13 (whether or not PCV7 or PPSV23 doses were previously administered)
 - Minimum interval of 8 weeks since the last dose of PCV7 or PPSV23 or between doses given at/after age 12 months

*Refer to “Recommended Schedule for Administering Doses of PCV13” for more details (www.michigan.gov/immunize)

Further Points

- High risk children ages 24-71 months include: a) immunocompetent (chronic lung or heart disease, diabetes, cochlear implant, cerebrospinal fluid (CSF) leak, b) immunocompromised (HIV, chronic renal or nephrotic syndrome, chemotherapy or radiation therapy for neoplasms, leukemia, lymphoma) and c) functional or anatomic asplenia (no spleen, sickle cell disease)
- For children ages 6-18 years with functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak, consider an additional (supplemental) dose of PCV13
- PCV13 will replace PCV7. PCV13 contains an additional 6 serotypes against *Streptococcus pneumoniae* & includes 19a, which is the most common pneumococcal serotype and often resistant to antibiotics.
- Use the current VIS for PCV or the Multi-Vaccine VIS that includes information about MI Care Improvement Registry (MCIR)
- VISs are available at www.michigan.gov/immunize or at your local health department.
- Document as “PCV13” (Prevnar 13) in MCIR and PCV13 on the vaccine administration record & immunization record card

¹ Children aged 2 years & older with asplenia (functional or anatomic) should complete a PCV series (including supplemental dose of PCV13) then wait a minimum interval of 4 weeks before receiving MCV/Menactra® (sanofi pasteur); may give MCV4/Menveo® (Novartis) at any interval.

References: “Prevention of Pneumococcal Disease in Infants and Children: Use of PCV13 & PPSV23” 12/10/10; “Recommendations of ACIP on Use of MCV4/MenACWY-D for aged 9-23 months at Increased Risk for Meningococcal Disease” 10/14/11 located at <http://www.cdc.gov/vaccines/recs>.

Updates of this Quick Look handout are posted at: www.michigan.gov/immunize.

Publicly-purchased PCV13 can be administered to eligible children 6 weeks through 18 years of age through the Vaccines for Children (VFC) Program in private providers’ offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information.

January 11, 2012



Recommended Schedule for Administering Doses of PCV13

(Pneumococcal Conjugate Vaccine; Prevnar13™, Wyeth)

Age at this Visit	Vaccination History: Total number of PCV7 and/or PCV13 doses previously received	Recommended PCV13 Dose(s) ¹
2-6 months	0 doses	3 doses, 8 weeks apart; 4 th dose at age 12-15 months
	1 dose	2 doses, 8 weeks apart; 4 th dose at age 12-15 months
	2 doses	1 dose, 8 weeks after the last dose; 4 th dose at age 12-15 months
7-11 months	0 doses	2 doses, 8 weeks apart 3 rd dose at 12-15 months
	1 or 2 doses before age 7 months	1 dose at age 7-11 months; 2 nd dose at age 12-15 months (at least 8 weeks later)
12-23 months	0 doses	2 doses, at least 8 weeks apart
	1 dose before age 12 months	2 doses, at least 8 weeks apart
	1 dose at/after age 12 months	1 dose, at least 8 weeks after the last dose ²
	2 or 3 doses before age 12 months	1 dose, at least 8 weeks after the last dose ²
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 additional dose, at least 8 weeks after the last dose ³
Healthy Children 24-59 months	Any incomplete schedule	1 dose, at least 8 weeks after the last dose ²
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 additional dose, at least 8 weeks after the last dose ³
High Risk Children 24-71 months ⁴	Any incomplete series of 2 <u>or</u> less doses	2 doses, one at least 8 weeks after the last dose and another dose at least 8 weeks later
	Any incomplete series of 3 doses	1 dose, at least 8 weeks after the last dose
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 additional dose, at least 8 weeks after the last dose ³
High Risk Children 6-18 years ⁵	Whether or not any previous doses of PCV7 or PPSV23 were given	May give one dose, at least 8 weeks after the last PCV7 or PPSV23 dose

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at ages less than 12 months, then the minimum interval is 4 weeks.
- 2) No additional PCV13 doses are indicated for children ages 12 through 23 months who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.
- 3) A single additional dose of PCV13 given at least 8 wks after the last dose of PCV7 is recommended for children ages 14-59 months who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 series (fully vaccinated with PCV7). For children with underlying medical conditions, an additional dose is recommended through age 71 months.
- 4) Children ages 24-71 months with one of the following medical conditions should receive an additional dose of PCV13:
 - Immunocompetent: chronic heart and lung disease, diabetes, cerebrospinal fluid leaks, cochlear implants
 - Immunocompromised: HIV, chronic renal failure or nephrotic syndrome, or diseases associated with immunosuppressive chemotherapy or radiation therapy including neoplasms, leukemia, lymphomas or solid organ transplant.
 - Sickle cell disease and other hemoglobinopathies; congenital or acquired asplenia or splenic dysfunction.
- 5) For children ages 6 through 18 years with functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak, consider an additional (supplemental) dose of PCV13

References: "Prevention of Pneumococcal Disease in Infants and Children: Use of PCV13 & PPSV23" 12/10/10; "Recommendations of ACIP on Use of MCV4/MenACWY-D for aged 9-23 months at Increased Risk for Meningococcal Disease" 10/14/11 located at www.cdc.gov/vaccines; "Quick Look to Using Prevnar (PCV13)" at <http://www.michigan.gov/immunize> January 11, 2012